Join experts David Morris, MD, FACS, and Benjamin Garmezy, MD, as they discuss the barriers and considerations in prescribing triplet therapy, offering insight into its benefits and how collaborative care between urologists and medical oncologists ensures a seamless patient journey.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.